US4255419A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Zinc deficiency in multiple sclerosis
Assignee: Allergan Inc
•
Filing: 1979-09-27
•
Granted: 1981-03-10
•
Expires: 1999-09-27
Abstract
Abstract Low serum zinc concentrations in humans have been associated with multiple sclerosis in some patients, particularly those patients under 50 years of age. Increasing the concentration of serum zinc in such patients has been found to lower the number of, or decrease the severity of recurrent attacks and/or improve neurologic function in some patients.
Inventors
- 👤 Irving H. Leopold
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 23:41
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/24; A61K33/30
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
30 words
A method of treating multiple sclerosis in a human having multiple sclerosis and having lower than normal concentrations of serum zinc comprising elevating the serum zinc level in said human.
Claim 2
Independent Claim
30 words
A method of treating multiple sclerosis in a human having multiple sclerosis and having lower than normal concentrations of serum zinc comprising elevating the serum zinc level in said human.
Claim 3
Independent Claim
46 words
A method of treating multiple sclerosis in a human having multiple sclerosis and having lower than normal concentrations of serum zinc comprising elevating the serum zinc concentration in said human by oral administration to said human of an effective, non-toxic zinc serum-elevating amount of ingestible zinc.
Claim 4
Independent Claim
46 words
A method of treating multiple sclerosis in a human having multiple sclerosis and having lower than normal concentrations of serum zinc comprising elevating the serum zinc concentration in said human by oral administration to said human of an effective, non-toxic zinc serum-elevating amount of ingestible zinc.
Claim 5
Dependent Claim
14 words
The method of claim 2, wherein said ingestible zinc is a non-toxic zinc salt.
Claim 6
Dependent Claim
21 words
The method of claim 3, wherein said zinc salt is selected from the group consisting of zinc sulfate and zinc carbonate.
Claim 7
Independent Claim
46 words
A method of treating multiple sclerosis in a human having multiple sclerosis and having lower than normal concentrations of serum zinc comprising elevating the serum zinc concentration in said human by oral administration to said human of an effective, non-toxic zinc serum-elevating amount of zinc sulfate.
Claim 8
Independent Claim
46 words
A method of treating multiple sclerosis in a human having multiple sclerosis and having lower than normal concentrations of serum zinc comprising elevating the serum zinc concentration in said human by oral administration to said human of an effective, non-toxic zinc serum-elevating amount of zinc sulfate.
Claim 9
Dependent Claim
15 words
The method of claim 5, wherein an effective amount is approximately 50-500 mg per day.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-03-09 | 1984-09-08 | 1985-03-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-03-09 | 1988-09-08 | 1989-03-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-03-09 | 1992-09-08 | 1993-03-10 | $7700.00 | Window Closed / Lapsed |